7575 Gateway Boulevard
Suite 110
Newark, CA 94560
United States
510 293 8800
https://www.cymabay.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 59
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Sujal A. Shah | Pres, CEO & Director | 873.87k | N/A | 1973 |
Dr. Dennis D. Kim M.B.A., M.D., MBA | Chief Medical Officer | 406.11k | N/A | 1970 |
Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA | Chief Commercial Officer | 378.79k | N/A | 1959 |
Mr. Daniel Menold | VP of Fin. | N/A | N/A | 1970 |
Dr. Charles A. McWherter Ph.D. | Sr. VP, Pres of R&D and Chief Scientific Officer | N/A | N/A | 1955 |
Mr. Paul T. Quinlan | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | N/A | N/A | 1963 |
Mr. Ken Boehm | Sr. VP of HR | N/A | N/A | N/A |
Mr. Patrick J. O'Mara | Sr. VP of Bus. Devel. | N/A | N/A | 1961 |
Dr. Robert L. Martin | Sr. VP of Manufacturing & Nonclinical Devel. | N/A | N/A | 1962 |
Ms. Klara A. Dickinson-Eason | Chief Regulatory & Quality Assurance Officer | N/A | N/A | 1968 |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
CymaBay Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 9. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 6; Compensation: 10.